A sensitive and reliable quantitative immunohistochemistry technique to evaluate the percentage of Trypanosoma cruzi-infected tissue area

Carregando...
Imagem de Miniatura
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Citação
PARASITOLOGY INTERNATIONAL, v.80, article ID 102210, 5p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Quantification of parasites in the context of Chagas disease is required to monitor the treatment with benznidazole, disease-associated cardiomyopathies and graft rejection after heart transplantation. As parasitological exams lack sensitivity, Real Time Polymerase Chain Reaction (rt-PCR) has emerged to evaluate the parasite load in blood samples and cardiac biopsies. However, despite its higher sensitivity, rt-PCR does not provide information on the location and distribution of amastigote nests within infected tissues, the characterization of inflammatory infiltrates or changes to tissue architecture. On the contrary, a sensitive immunohistochemistry technique (IHC) could fill these gaps. In the present study, a quantitative IHC exam was standardized and validated by testing adipose and cardiac tissues of experimentally infected mice containing variable parasite load levels of T. cruzi assessed by a sensitive Sybr Green rt-PCR with kDNA primers. Tissues were divided into four groups according to the parasite load: group A100 parasites/50 ng of DNA; group B-10 parasites; group C - around 1 parasite and group D less than 1 parasite/50 ng/DNA. IHC was able to detect T. cruzi in the four groups, even in group D tissues containing fractions of a single parasite/50 ng of DNA sample according to rt-PCR. In conclusion, a highly sensitivity and reliable quantitative immunohistochemistry technique was developed and is proposed to estimate the percentage of T. cruzi-infected tissue area in chagasic patients presenting with cardiomyopathies, as a complementary test to rt-PCR.
Palavras-chave
Cardiomyopathy, Cardiac biopsies, Endomyocardial biopsies, Anti-T. cruzi antibodies
Referências
  1. Bilate AM, 2008, J INFECT DIS, V198, P614, DOI 10.1086/590347
  2. Caldas S, 2012, ACTA TROP, V123, P170, DOI 10.1016/j.actatropica.2012.05.002
  3. Caliari MV, 2002, VIRCHOWS ARCH, V441, P69, DOI 10.1007/s00428-001-0542-4
  4. Cobo ED, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/232646
  5. Ezyaguirre E.J., 2011, DIAGNOSTIC IMMUNOHIS, P58, DOI [10.1016/B978-1-4160-5766-6.00007-8, DOI 10.1016/B978-1-4160-5766-6.00007-8]
  6. Greenfield E.A., 2014, ANTIBODIES LAB MANUA, P2014
  7. Guarner J, 2001, AM J TROP MED HYG, V65, P152, DOI 10.4269/ajtmh.2001.65.152
  8. HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
  9. Lewis MD, 2016, TRENDS PARASITOL, V32, P899, DOI 10.1016/j.pt.2016.08.009
  10. Dias JCP, 2016, REV SOC BRAS MED TRO, V49, P3, DOI 10.1590/0037-8682-0505-2016
  11. Portela-Lindoso AAB, 2003, REV SAUDE PUBL, V37, P107, DOI 10.1590/S0034-89102003000100016
  12. Azevedo PHR, 2018, REV SOC BRAS MED TRO, V51, P467, DOI 10.1590/0037-8682-0011-2018
  13. Ferreira JCR, 2019, EXP PARASITOL, V200, P13, DOI 10.1016/j.exppara.2019.03.007
  14. Santoro F, 1987, Rev Soc Bras Med Trop, V20, P91, DOI 10.1590/S0037-86821987000200005
  15. Simões Marcus Vinicius, 2018, Int. J. Cardiovasc. Sci., V31, P173, DOI 10.5935/2359-4802.20180011
  16. YOUNESCHENNOUFI AB, 1988, T ROY SOC TROP MED H, V82, P77, DOI 10.1016/0035-9203(88)90269-6